Consolidative radioimmunotherapy after chemoimmunotherapy in patients with histologic transformation of indolent non Hodgkin lymphoma

Abstract Introduction Histologic transformation of indolent non Hodgkin lymphomas is an event that results in considerable morbidity and mortality. The introduction of chemoimmunotherapy regimens has resulted in an improvement in the management of this disease, and consolidation of responses with au...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2016-06, Vol.16 (6), p.322-328.e2
Hauptverfasser:	Reagan, Patrick M., MD, Baran, Andrea, MS, Kelly, Jennifer L., PhD MPH, Barr, Paul M., MD, Casulo, Carla, MD, Chengazi, Vaseem U., MD PhD, Friedberg, Jonathan W., MD MMSc
Format:	Artikel
Sprache:	eng
Schlagworte:	131I-tositumomab 90Y-ibritumomab tiuxetan Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cause of Death Cell Transformation, Neoplastic Combined Modality Therapy Female Hematology, Oncology and Palliative Medicine Humans Immunotherapy indolent lymphoma Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - pathology Lymphoma, Non-Hodgkin - therapy Male Middle Aged radioimmunoconjugate Radioimmunotherapy - methods Retreatment Retrospective Studies Survival Analysis transformed lymphoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!